MedTrace Logo

Expanded Access Remdesivir (RDV; GS-5734™)

NCT04302766 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2022-02-17

No results posted yet for this study

Summary

Disease caused by 2019 Novel Coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Conditions

  • Coronavirus Disease 2019

Interventions

DRUG

Remdesivir

Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).

Sponsors & Collaborators

  • U.S. Army Medical Research and Development Command

    lead FED

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Afghanistan
  • Djibouti
  • Germany
  • Guam
  • Iraq
  • Japan
  • Kuwait

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04302766 on ClinicalTrials.gov